Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Flumazenil discrimination by humans under a two-response and a novel-response procedure
Autore:
Smith, BJ; Bickel, WK;
Indirizzi:
Univ Vermont, Dept Psychiat, Burlington, VT USA Univ Vermont Burlington VT USA ermont, Dept Psychiat, Burlington, VT USA Univ Vermont, Dept Psychol, Burlington, VT 05405 USA Univ Vermont Burlington VT USA 05405 pt Psychol, Burlington, VT 05405 USA
Titolo Testata:
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
fascicolo: 3, volume: 291, anno: 1999,
pagine: 1257 - 1268
SICI:
0022-3565(199912)291:3<1257:FDBHUA>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
BENZODIAZEPINE RECEPTOR ANTAGONIST; DOSE CAFFEINE DISCRIMINATION; DRUG DISCRIMINATION; RO 15-1788; TRIAZOLAM DISCRIMINATION; STIMULUS PROPERTIES; AGONIST PROPERTIES; D-AMPHETAMINE; RO-15-1788; WITHDRAWAL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Smith, BJ Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Behav Biol Res Ctr, 5510 Nathan Shock Dr,Suite 3000, Baltimore, MD 21224 USA Johns Hopkins Univ 5510 Nathan Shock Dr,Suite 3000 Baltimore MD USA 21224
Citazione:
B.J. Smith e W.K. Bickel, "Flumazenil discrimination by humans under a two-response and a novel-response procedure", J PHARM EXP, 291(3), 1999, pp. 1257-1268

Abstract

In this study we assessed the discriminative stimulus, self-reported, and performance effects of flumazenil in humans. The first group (n = 6) was trained to discriminate flumazenil (0.56 mg/70 kg i.v.) from saline and tested with flumazenil (0.10, 0.32, 0.56, and 1.0 mg/70 kg) under a two-responsedrug discrimination procedure. The second group (n = 8) was trained to discriminate flumazenil (0.56 mg/70 kg i.v.) from saline and tested with flumazenil (0.32, 0.56, and 1.0 mg/70 kg), midazolam (0.10, 0.56, and 1.0 mg/70 kg), and caffeine (75 mg/70 kg) under a novel-response drug discrimination procedure. In both groups, flumazenil was acquired and maintained as a discriminative stimulus. Flumazenil dose-dependently increased flumazenil-appropriate responding and ratings of strength of drug effect and sedation, and decreased ratings of stimulant effects and psychomotor performance. Under the novel-response procedure, midazolam produced dose-dependent increases influmazenil-appropriate responding. However, midazolam produced 43 and 25% novel responding at the intermediate and highest test doses, respectively. Midazolam dose-dependently increased ratings of strength of drug effect andsedation, and decreased ratings of stimulant effects and psychomotor performance. The magnitude of effects on ratings of strength of drug effect and sedation were comparable after flumazenil and midazolam, but psychomotor performance effects were greater after midazolam than after flumazenil. Caffeine produced mostly saline-appropriate responding. The results indicate that flumazenil has agonist effects similar to those of midazolam; however, novel responding after midazolam, and the greater performance decrement aftermidazolam, suggest that flumazenil does not act as a traditional benzodiazepine agonist.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 23:18:51